2016 VAM: 1008 - Pathogenesis of Chronic Rhinosinusitis
AMA PRA Category 1 Credits™: 2.50
CE: 2.50
Credit must be claimed by May 31, 2018. Any credit request on or after June 1, 2018 will be subject to an administrative fee.
Target Audience
Physicians
Allergists/Immunologists
Nurses
Nurse Practitioners
Allied Health Professionals
Learning Objectives
Upon completion of this session, participants should be able to:
1. Discuss the role of TSLP and its metabolic products in the inflammation of nasal polyps
2. Recognize the mechanisms by which IL-33 contributes to the pathogenesis of CRS with nasal polyps and the potential to target this cytokine in therapy
3. Identify the mechanisms by which PGD2 directs inflammation in rhinosinusitis and nasal polyps and become aware of unique aspects of the pathology and pathophysiology of nasal polyp disease in Asia and in Europe
Additional Information
Attachment | Size |
---|---|
2016 Annual Meeting Disclosures | 120.13 KB |
Claus Bachert, MD PhD, Universitair Ziekenhuis Gent, Ghent, Belgium
Joshua A. Boyce, MD FAAAAI, Brigham and Women's Hospital, Boston, MA
Katherine N. Cahill, MD, Harvard Medical School, Boston, MA
Atsushi Kato, PhD, Northwestern University Feinberg School of Medicine, Chicago, IL
Marek L. Kowalski, MD PhD, Medical University of Lodz, Lodz, Poland
Available Credit
- 2.50 AttendanceAttendance credit.
- 2.50 CECE credit.
- 2.50 CMECME credit.